Check 35,000+ stocks against 26 valuation models and 37 quality factors

Jinyu Bio-Technology Co Ltd (600201) fair value: what the stock is really worth

We calculate from audited financials what Jinyu Bio-Technology Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · CN · ISIN CNE000000Y37

JB Thin data Sep 13, 2026

Jinyu Bio-Technology Co Ltd

600201 · SHG

Stretched ValuationQuality growthStrong overvaluation with only moderate quality.

!Fair value ¥6.40 · Strongly overvalued (−45%)

!Quality 64/100

!Weak Growth (revenue 5y −2.5 %/yr)

!Thin margins · 9.4% net margin (TTM)

✓Low debt · generates free cash flow

·0.32% dividend yield

!Mixed vs. peers (7/14)

!Narrow moat 43/100

!Evidence only low, so the estimate is less certain

!Weak on past: 11 out of 100

!Weak on dividend: 6 out of 100

26 models, one by oneBear ¥5.74 to bull ¥6.40 Growth analysisrevenue history, year by year Quality 64/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Jinyu Bio-Technology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range ¥5.67 – ¥21.27 · fair‑value band ¥5.74 – ¥6.40 · the ¥11.69 price screens above the ¥6.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.

Stock analysis

Jinyu Bio-Technology Co Ltd (600201) currently trades at ¥11.69, while our model-based Fair Value estimate is ¥6.40, implying the stock looks roughly 82.6% overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of ¥3.74 per share, and 0 of the 26 models we run sit above the ¥11.69 price.

Bear case: the Earnings-Based group reads lowest at ¥0.7600, and 26 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥5.74 (bear) to ¥6.40 (bull), the price of ¥11.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Jinyu Bio-Technology Co Ltd reported revenue of 1.4B CNY in FY2025 versus 1.8B CNY in FY2021, a compound −5.8%/yr. Reported net income was 100M CNY in FY2025, compounding −28.5%/yr from FY2021.

Key figures

Market cap 14.5B CNY (≈ $2.2B) · P/E ratio 89.9 · P/S ratio 6.45 · EPS (TTM) ¥0.1300 · Dividend yield 0.3% · Net margin 7.2% · Return on equity 1.8% · Return on assets (EBIT) 3.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 62% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −45%, 600201 screens richer than that median.

Fair Value models

Bear ¥5.74 Fair Value ¥6.40 Bull ¥6.40

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.0373 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ¥3.21 ¥4.55 ¥6.70 80

Growth DCF ¥3.23 ¥4.54 ¥6.63 78

Owner Earnings ¥3.67 ¥5.31 ¥7.92 76

All 26 models by family

DCF Models

FCF DCF ¥3.21 ¥4.55 ¥6.70 80

Owner Earnings ¥3.67 ¥5.31 ¥7.92 76

5Y Revenue Exit ¥2.46 ¥3.15 ¥4.02 74

5Y EBITDA Exit ¥3.97 ¥6.08 ¥8.61 75

5Y P/E Exit ¥2.72 ¥3.66 ¥4.65 72

10Y Revenue Exit ¥2.68 ¥3.39 ¥4.35 68

10Y EBITDA Exit ¥3.68 ¥5.46 ¥7.96 68

10Y P/E Exit ¥2.88 ¥3.74 ¥4.84 65

Earnings-Based

Graham-Dodd ¥0.6100 ¥2.24 ¥3.03 64

Lynch FV ¥0.5300 ¥0.7600 ¥0.9900 61

PEG = 1.0 ¥0.5300 ¥0.7600 ¥0.9900 57

EPV ¥1.98 ¥2.12 ¥2.24 74

Dividend Discount

Gordon GGM ¥0.2800 ¥0.5700 ¥0.9100 66

DDM Multi-Stage ¥0.2800 ¥0.4800 ¥0.6000 67

Multiples

P/E Multiple ¥1.49 ¥1.99 ¥2.48 63

P/S Multiple ¥1.15 ¥1.54 ¥1.92 58

P/B Multiple ¥1.15 ¥1.54 ¥1.92 55

EV/EBIT ¥2.50 ¥2.96 ¥3.42 66

EV/EBITDA ¥4.71 ¥5.91 ¥7.10 67

EV/Revenue ¥2.11 ¥2.53 ¥2.95 54

Asset-Based

NCAV (Graham) ¥2.42 ¥3.24 ¥4.84 54

Growth DCF

Growth DCF ¥3.23 ¥4.54 ¥6.63 78

Rev-Margin DCF ¥2.46 ¥3.16 ¥4.01 74

Economic Profit

Residual Income ¥3.39 ¥3.21 ¥2.51 76

ROIC Compounder ¥1.98 ¥2.12 ¥2.24 72

Growth Earnings

Growth-Adj P/E ¥1.04 ¥1.48 ¥1.92 67

Open the full fair value analysis →

Notify me when 600201 reaches fair value

Put 600201 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 63 · Market factors (momentum, volatility) 52

Profitability 22

Margins and returns on capital today

Quality Growth 45

Are margins and returns improving?

Cashflow 72

Earnings quality: real cash, not paper profit

Fin. Strength 93

Balance sheet, leverage, solvency risk

Investment 83

Disciplined investing over empire-building

Low Volatility 59

Calm price path (market factor)

Momentum 47

Price trend over the last 3–12 months (market factor)

52W Momentum 54

Distance to the 52-week high (market factor)

Net Issuance 72

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+11.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−3.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−2.5%

Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−23.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year−23.3%

Dividend (yield on the price)0.3%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−23% vs −15%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 9%

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+30.2%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

600201 screens 83% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Jinyu Bio-Technology Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks

Beats the industry median on 7/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 64 · Top 25%

Fair Value upside −84% · Bottom 25%

Profitability

Return on equity (TTM) 3% · Above median

Return on assets 1% · Above median

Net margin (TTM) 9% · Above median

Operating margin (TTM) 20% · Top 25%

Growth and dividend

Revenue growth 53% · Top 25%

Dividend yield (TTM) 0.3% · Bottom 25%

Balance sheet

Debt / equity 0.00× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 89.9× · Priciest 25%

P/B 2.70× · Pricier than median

P/S (TTM) 9.46× · Pricier than median

P/FCF 11.1× · Pricier than median

EV/EBITDA 35.1× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)11 · sector 0

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)6 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$515.44	$566.98	+10%
Regeneron Pharmaceuticals, Inc REGN	$781.49	$1,241	+59%
argenx SE ARGX	€853.80	€752.12	−12%
BeOne Medicines AG 688235	¥247.30	¥124.62	−50%
Samsung Biologics Co 207940	1,415,000 KRW	1,556,500 KRW	+10%
Alnylam Pharmaceuticals, Inc ALNY	$248.68	$211.88	−15%
Royalty Pharma plc RPRX	$58.61	$24.22	−59%
Celltrion, Inc 068270	178,200 KRW	74,519 KRW	−58%
BioNTech SE BNTX	$96.73	$63.31	−35%
Incyte Corporation INCY	$121.47	$204.93	+69%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jinyu Bio-Technology Co Ltd · Fair Value
¥6.40 −83%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/600201" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Jinyu Bio-Technology Co Ltd · Fair Value</span><br><b style="font-size:20px">¥6.40</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−83%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Jinyu Bio-Technology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600201

Frequently asked questions

Is Jinyu Bio-Technology Co Ltd (600201) overvalued or undervalued?

As of Sep 13, 2026, our model estimates a fair value of ¥6.40 versus a price of ¥11.69, about −45% upside (overvalued).

What is the fair value of 600201?

Our model-based fair value for Jinyu Bio-Technology Co Ltd is ¥6.40 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥11.69.

What is the quality score of 600201?

Jinyu Bio-Technology Co Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Jinyu Bio-Technology Co Ltd (600201)?

Our model-based price target is the fair value of ¥6.40 (as of Sep 13, 2026) from 26 valuation models. Cautious scenario ¥5.74, optimistic scenario ¥6.40. It is a calculation from audited fundamentals, not an analyst target.

What is the Jinyu Bio-Technology Co Ltd stock forecast for 2026?

Our models put fair value at ¥6.40, about −45% upside versus a price of ¥11.69 (overvalued). Cautious scenario ¥5.74, optimistic scenario ¥6.40. The calculation is refreshed regularly with new filings.

What is the revenue of Jinyu Bio-Technology Co Ltd (600201)?

Jinyu Bio-Technology Co Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Sep 13, 2026).

Does Jinyu Bio-Technology Co Ltd pay a dividend?

Jinyu Bio-Technology Co Ltd currently shows a dividend yield of about 0.32% relative to its recent price (as of Sep 13, 2026).

What growth is priced into Jinyu Bio-Technology Co Ltd (600201)?

For today's price to be fair in a discounted-cash-flow model, Jinyu Bio-Technology Co Ltd would have to grow free cash flow by +30.2 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.5 % per year. As of Sep 13, 2026.

What discount rate (WACC) does the fair value of 600201 use?

Our models discount Jinyu Bio-Technology Co Ltd at 9.5 %: a base by market capitalisation (mid), damped by beta 0.65, country premium for China. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jinyu Bio-Technology Co Ltd that is +30.2 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.

How much growth has Jinyu Bio-Technology Co Ltd (600201) delivered so far?

Over the past 5 years revenue at Jinyu Bio-Technology Co Ltd grew -2.5 % a year. The price currently implies +30.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Jinyu Bio-Technology Co Ltd (600201) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Jinyu Bio-Technology Co Ltd (+30.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Jinyu Bio-Technology Co Ltd (600201)?

The free-cash-flow yield on the price is 1.50 %: that much free cash flow Jinyu Bio-Technology Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Jinyu Bio-Technology Co Ltd (600201)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jinyu Bio-Technology Co Ltd it is ¥6.40 per share (as of Sep 13, 2026), against a price of ¥11.69. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Jinyu Bio-Technology Co Ltd stock overvalued or undervalued in 2026?

As of Sep 13, 2026, 600201 trades above its calculated fair value: price ¥11.69, fair value ¥6.40, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 600201?

No. The price is what the market pays today (¥11.69); the fair value is what the company's own numbers justify (¥6.40). For Jinyu Bio-Technology Co Ltd the two are ¥5.29 per share apart. That gap is exactly why we show both numbers side by side.

How much is Jinyu Bio-Technology Co Ltd worth?

The market values Jinyu Bio-Technology Co Ltd at about 14.5B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥11.69; our models calculate a fair value of ¥6.40 per share.

What do the bullish and bearish scenarios say about 600201?

Our models span a range for Jinyu Bio-Technology Co Ltd: cautious scenario ¥5.74, base ¥6.40, optimistic ¥6.40 per share (as of Sep 13, 2026, price ¥11.69). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 600201?

Jinyu Bio-Technology Co Ltd trades at a price-to-earnings ratio of 89.9 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.40 is built from several models across several years. Other multiples: P/B 2.7, P/S 9.5, EV/EBITDA 35.1.

How solid is the balance sheet of Jinyu Bio-Technology Co Ltd (600201)?

Balance-sheet figures for Jinyu Bio-Technology Co Ltd (as of Sep 13, 2026): return on equity 2.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.

How far is 600201 from its 52-week high?

Jinyu Bio-Technology Co Ltd trades at ¥11.69, about 38% below its 52-week high of ¥19.00 and 62% above the low of ¥7.22 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.40 is for.

Which stocks are comparable to Jinyu Bio-Technology Co Ltd?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Jinyu Bio-Technology Co Ltd stock attractive at the current price?

The data as of Sep 13, 2026: price ¥11.69, calculated fair value ¥6.40 (−45%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 600201 calculated?

We run Jinyu Bio-Technology Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.40, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 15.8 % above its aggregate fair value. Jinyu Bio-Technology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What should I pay attention to with Jinyu Bio-Technology Co Ltd right now?

The price sits above even our optimistic bull case (¥6.40). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥5.74 to ¥6.40), unusually little disagreement for a valuation.

Where does the earnings growth of Jinyu Bio-Technology Co Ltd (600201) come from?

Earnings per share at Jinyu Bio-Technology Co Ltd grew −7.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share +3.7 %, EBIT margin −10.7 %, tax rate +0.4 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Jinyu Bio-Technology Co Ltd

How large is the market capitalisation of Jinyu Bio-Technology Co Ltd (600201)?

The market capitalisation of Jinyu Bio-Technology Co Ltd is 14.5B CNY (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Jinyu Bio-Technology Co Ltd (600201)?

The price-to-sales ratio of Jinyu Bio-Technology Co Ltd is 6.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Jinyu Bio-Technology Co Ltd (600201)?

Earnings per share at Jinyu Bio-Technology Co Ltd are ¥0.1300 (price ÷ EPS = P/E 89.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Jinyu Bio-Technology Co Ltd (600201)?

The dividend yield of Jinyu Bio-Technology Co Ltd is 0.3% (payout 28.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Jinyu Bio-Technology Co Ltd (600201)?

The net margin of Jinyu Bio-Technology Co Ltd is 7.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Jinyu Bio-Technology Co Ltd (600201)?

The return on equity (ROE) of Jinyu Bio-Technology Co Ltd is 1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Jinyu Bio-Technology Co Ltd (600201)?

On an EBIT basis the return on assets of Jinyu Bio-Technology Co Ltd is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Jinyu Bio-Technology Co Ltd (600201)?

The operating margin of Jinyu Bio-Technology Co Ltd is 20.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Jinyu Bio-Technology Co Ltd (600201)?

Revenue at Jinyu Bio-Technology Co Ltd is growing −1.5% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much net cash does Jinyu Bio-Technology Co Ltd (600201) hold?

Jinyu Bio-Technology Co Ltd holds more cash than debt, 1.1B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Jinyu Bio-Technology Co Ltd in the live analysis

One click puts Jinyu Bio-Technology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.